Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P35125

UPID:
UBP6_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 6; Proto-oncogene TRE-2; Ubiquitin thioesterase 6; Ubiquitin-specific-processing protease 6

ALTERNATIVE UPACC:
P35125; Q15634; Q86WP6; Q8IWT4

BACKGROUND:
Ubiquitin carboxyl-terminal hydrolase 6, also referred to as Proto-oncogene TRE-2 or Ubiquitin thioesterase 6, is integral to deubiquitination processes within the cell. It uniquely performs ATP-independent isopeptidase activity, specifically cleaving ubiquitin moieties at their C-terminus and facilitating its own deubiquitination. Among its isoforms, isoform 2 is active in deubiquitinating activities in vitro, unlike isoform 3. This protein is instrumental in ensuring the plasma membrane presence of ARF6 and is involved in the selective regulation of ARF6-dependent pathways for endocytic protein trafficking. Furthermore, its role in tumorigenesis, through the activation of NF-kappa-B and subsequent production of matrix metalloproteinases, highlights its potential impact on cellular functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin carboxyl-terminal hydrolase 6 offers a promising avenue for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.